Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer

Journal of Clinical Investigation(2022)10.1172/jci145099Source: DataRank Database

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer is a research paper published in Journal of Clinical Investigation (2022). On theSindex it has a DataRank of 1.8. It has been cited 59 times, with 55 citing works in its 1-hop citation network.

N/A

1.8DataRank · unranked

Scored on demand from live citation data

Open Access59 citations · 55 citing works in its network

Download PDF

Cite:

Linked data & code

geo bioproject nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)OA: goldTopics (54)IDs (PubMed, PMC)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 35%Citation Network 65%

Base Score Contribution

0.614

From this paper's citation signal

Citation Network Contribution

1.1

From 41 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 55 citers.

Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD)
Biomedicines2023112 citations49 referencesContributes 0.096
Unveiling potential: urinary exosomal mRNAs as non-invasive biomarkers for early prostate cancer diagnosis
BMC Urology202419 citations41 referencesContributes 0.073
RBM10 C761Y mutation induced oncogenic ASPM isoforms and regulated β-catenin signaling in cholangiocarcinoma
Journal of Experimental & Clinical Cancer Research202412 citations40 referencesContributes 0.064
Targeting dysregulated splicing factors in cancer: lessons learned from RBM10 deficiency
Journal of Molecular Cell Biology20235 citations32 referencesContributes 0.056
RBM10 Loss Promotes EGFR -Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Cancer Research202335 citations67 referencesContributes 0.053

Authors (28)

Wei Wu ORCID,Niki Karachaliou ORCID,Collin M. Blakely ORCID,Junji Suzuki ORCID,Yu‐Ting Chou ORCID

Live enrichment

PubMed:35579943 PMC:PMC9246391

National Institutes of Health

Grant: R01CA231300

National Institutes of Health

Grant: U54CA224081

National Institutes of Health

Grant: R01CA204302

National Institutes of Health

Grant: R01CA211052

National Institutes of Health

Grant: R01CA169338

National Institutes of Health

Grant: K08CA222625

JSPS KAKENHI

Grant: 21K15546

NCI NIH HHS

Grant: T32 CA108462

National Institutes of Health

Grant: 5R01CA169338-02

Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment

National Institutes of Health

Grant: 5R01CA211052-03

Optimizing biologically-based rational polytherapy in ALK+ lung cancer

National Institutes of Health

Grant: 5R01CA231300-03

(PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules

National Institutes of Health

Grant: 3U54CA224081-01S1

Bay Area Team Against Resistance

National Institutes of Health

Grant: 5K08CA222625-02

Therapeutic rescue of the transcriptional repressor Capicua to inhibit lung cancer metastasis

National Institutes of Health

Grant: 1R01CA204302-01A1

Characterization of YAP as a rational companion target in lung cancer

goldLicense: cc-by

publisherhttp://www.jci.org/articles/view/145099/files/pdf

publisherhttps://www.jci.org/articles/view/145099/files/pdf

repositoryhttps://escholarship.org/uc/item/9qv6c73z

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9246391

Europe_PMChttps://europepmc.org/articles/PMC9246391

Fields of Study

0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

Cell Line, TumorHumansLung NeoplasmsFactor XRNA-Binding ProteinsRNA, MessengerProtein Kinase InhibitorsApoptosisErbB ReceptorsRNA Splicing FactorsRNA-Binding Motifs

Keywords

Lung cancerCancer gene therapyTherapeuticsOncology570Biomedical and clinical sciencesLung NeoplasmsClinical SciencesOncology and CarcinogenesisMessengerImmunology610ApoptosisMedical and Health SciencesCell LineRare DiseasesClinical ResearchCell Line, TumorGenetics2.1 Biological and endogenous factorsHumansRNA, MessengerLungProtein Kinase InhibitorsCancerTumorRHealth sciencesRNA-Binding ProteinsBiological SciencesErbB Receptors5.1 PharmaceuticalsFactor XRNA-Binding MotifsWomen's HealthRNAMedicineBiochemistry and Cell BiologyRNA Splicing FactorsResearch Article

Sustainable Development Goals

SDG 3: 3. Good health